For research use only. Not for use in humans.

Icatolimab (Anti-BTLA / CD272)

Synonyms: CD272, B and T lymphocyte attenuator

Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD.

Icatolimab (Anti-BTLA / CD272)

Quality Control

Batch: A258101 Purity: 99% Protein concentration: 3.59mg/ml Endotoxin Level: <1EU/mg
99

Mechanism of Action

Description
Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD.

Product Details

Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05781451 WITHDRAWN Drug: LY3361237 Primary Sjogren's Syndrome Stanford University 2025-01-01 PHASE2
NCT05789069 ACTIVE_NOT_RECRUITING Drug: HFB200603|Drug: Tislelizumab Renal Cell Carcinoma; Melanoma; Non Small Cell Lung Cancer; Gastric Cancer; Colorectal Cancer HiFiBiO Therapeutics 2023-05-09 PHASE1
NCT05664971 COMPLETED Drug: Docetaxel|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carbo Advanced Lung Cancer Shanghai Junshi Bioscience Co., Ltd. 2023-02-09 PHASE1; PHASE2
NCT05000684 COMPLETED Drug: JS004 in combination with toripalimab Advanced Lung Cancer Shanghai Junshi Bioscience Co., Ltd. 2021-08-27 PHASE1; PHASE2
NCT04477772 COMPLETED Recurrent/Refractory Malignant Lymphoma Shanghai Junshi Bioscience Co., Ltd. 2020-07-17 PHASE1
NCT05427396 TERMINATED Drug: JS004|Drug: Toripalimab Injection Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer Shanghai Junshi Bioscience Co., Ltd. 2022-07-28 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-04-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.